Eli Lilly (LLY)

These are great and steady income providers for your portfolio.

Moves Lilly has recently made should support a new potential source of growth.

GSAT, XOM, CYCN, LLY, INTC were among the stocks seen trending on Wednesday, April 1, 2026.

Its first weight-loss pill was just approved by the FDA.

Eli Lilly (LLY) shares rallied after finding support at a formed resistance level. They may hit resistance at a former support level.

Today, April 1, 2026, hopes that the Iran war may soon end drove markets upwards as tumbling oil prices reshaped the day’s winners.

INDIANAPOLIS — In a move that has sent shockwaves through the global financial markets, Eli Lilly and Company (NYSE: LLY) announced early this morning, April 1, 2026, a definitive agreement to acquire Contessa, a powerhouse in clinical research and next-generation pharmaceutical development. The massive $47.8 billion all-cash transaction represents the

The pharmaceutical giant still has plenty of work to do to recover from recent woes.

Eli Lilly stock rallies as the firm’s oral weight-loss pill, Foundayo, secures FDA approval. Options pricing suggests LLY shares will rip higher over the next three months.

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 4.7% in the afternoon session after the FDA approved Foundayo (orforglipro...

Eli Lilly shares surged after FDA approval of its oral obesity drug Foundayo, boosting growth prospects in the weight-loss market.

Eli Lilly stock jumped midday Wednesday after the FDA approved its weight-loss pill, now called Foundayo.

This pharmaceutical giant appears well positioned for a potential stock split in 2026.

Centessa Pharma to be acquired by Eli Lilly for $8B. Analyst downgrades rating. Deal includes $6.3B in cash and potential $1.5B in milestones.

Hasbro is expected to announce its first-quarter results soon, and analysts are projecting a single-digit decline in its EPS.

Nasdaq will release its first-quarter earnings soon, and analysts anticipate a double-digit bottom-line growth.

Willis Towers Watson will release its first-quarter earnings soon, and analysts anticipate a double-digit bottom-line growth.

A pharma giant wants to buy the innovative drug developer.

This little-known biotech company has a different strategy than the established weight-loss drug market leaders. But is it likely to be successful?

Eli Lilly to acquire Centessa Pharmaceuticals for $6.3B. CNTA stock surges 45% as Lilly expands its neuroscience and sleep medicine pipeline.

Today, March 31, 2026, the biotechnology landscape has been fundamentally reshaped. Eli Lilly and Company (NYSE: LLY) has officially announced a definitive agreement to acquire Centessa Pharmaceuticals (Nasdaq: CNTA) in a blockbuster transaction valued at up to $7.8 billion. This acquisition marks a watershed moment for the treatment of sleep-wake disorders and underscores the intense [...]

Date: March 31, 2026 Introduction In the spring of 2026, the global pharmaceutical landscape is increasingly defined by the gravitational pull of a single entity: Eli Lilly and Company (NYSE: LLY). Once a steady mid-tier giant known for insulin and antidepressants, Lilly has transformed into the world’s first trillion-dollar healthcare titan. Today’s announcement—a definitive $6.3 [...]

Eli Lilly has expanded its partnership with Insilico Medicine to bring AI developed medicine into global market.

The takeover fills a glaring hole in Eli Lilly's pipeline, says one analyst.